March 15, 2011

Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study

.   .   

This is another study assessing the role of belatacept, a costimulatory blocker in renal transplantation. As opposed to previous studies in de novo patients, this randomized controlled trial included patients 6 to 36 months post-transplant who continued on treatment with a calcineurininbitor or were switched to belatacept. There was a greater improvement in GFR after twelve months in the patients switched to belatacept. There were more rejections in the belatacept-treated patients, but no graft losses.

Related Articles:

Renal Transplantation

Comments are closed.